Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. SC Ropharma's annualized net income for the quarter that ended in Dec. 2024 was lei3 Mil. SC Ropharma's average shareholder tangible equity for the quarter that ended in Dec. 2024 was lei183 Mil. Therefore, SC Ropharma's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2024 was 1.63%.
The historical rank and industry rank for SC Ropharma's Return-on-Tangible-Equity or its related term are showing as below:
BSE:RPH's Return-on-Tangible-Equity is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 10.17 * Ranked among companies with meaningful Return-on-Tangible-Equity only.
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
SC Ropharma Return-on-Tangible-Equity Related Terms
SC Ropharma Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for SC Ropharma's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, SC Ropharma's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SC Ropharma Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, SC Ropharma's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where SC Ropharma's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2024) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 1.63% mean?
SC Ropharma (BSE:RPH) has a Return-on-Tangible-Equity of 1.63% as of Dec. 2024. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on SC Ropharma and its competitors.
Is SC Ropharma's Return-on-Tangible-Equity too high?
SC Ropharma's current Return-on-Tangible-Equity is 1.63%. The Healthcare Providers & Services industry median Return-on-Tangible-Equity is 10.17. SC Ropharma's value of 1.63% is 84% below this industry median. Overall, SC Ropharma has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does SC Ropharma's Return-on-Tangible-Equity compare to competitors?
SC Ropharma's Return-on-Tangible-Equity of 1.63% can be compared against companies in the Healthcare Providers & Services industry. The industry median Return-on-Tangible-Equity is 10.17. SC Ropharma's value of 1.63% is 84% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.17, based on 576 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SC Ropharma's current Return-on-Tangible-Equity of 1.63% is 84% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on SC Ropharma and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SC Ropharma's current Return-on-Tangible-Equity is 1.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SC Ropharma stock overvalued right now?
SC Ropharma (BSE:RPH) has a current Return-on-Tangible-Equity of 1.63%. The current Return-on-Tangible-Equity is 1.63% and 84% below the Healthcare Providers & Services industry median of 10.17. SC Ropharma's overall GF Score™ is 66/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For SC Ropharma (BSE:RPH), the current Return-on-Tangible-Equity is 1.63% as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SC Ropharma SA is engaged in the production, distribution, and Retail sale of pharmaceutical products in specialized stores. Its product portfolio comprises over 50 products in the form of tablets, powders, capsules, and syrups covering 21 therapeutic areas.
66GF Score
Get the complete analysis for BSE:RPH
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSE:RPH has been successfully added to your 
